Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE-1: olatorepatide in adults with overweight or obesity without diabetes
2025-524861-26-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Olatorepatide with Placebo for olatorepatide (2 arms). Primary endpoint: Percent change in body weight. Planned start Sep 2026; status: authorised.
02
Drugs
olatorepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-524861-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524861-26-00.